Primary breast lymphoma

Abstract Primary breast lymphoma is a rare entity that accounts for only 1% of malignant breast neoplasms. It is characterized by the presence of a breast lump, with or without associated regional adenopathy and without systemic involvement. Imaging findings are nonspecific, and diffuse large B-cell lymphoma is the most common histological type. Given its rarity, there is still no consensus on the best approach, with chemotherapy being the most accepted treatment. This article aims to present a literature review as well as to present a clinical case.

Download Full-text

170 Primary Breast Lymphoma-Mimicking Inflammatory Breast Disease: A Case Report

British Journal of Surgery ◽

10.1093/bjs/znab134.199 ◽

2021 ◽

Vol 108 (Supplement_2) ◽

Author(s):

R Alam ◽

B Basak ◽

A Ahsan ◽

A S Gupta ◽

S Islam ◽

...

Keyword(s):

Breast Carcinoma ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Primary Breast Lymphoma ◽

Palpable Mass ◽

Large B Cell Lymphoma ◽

Breast Lymphoma ◽

History Of ◽

Large B Cell

Abstract Primary breast lymphoma (PBL) is an unusual clinical entity accounting for 0.4–0.5% of all breast neoplasms. The usual presentation includes a painless palpable mass similar to that of breast carcinoma. Diffuse large B-cell lymphoma (DLBCL) is the most common identifiable type of PBL based on the histopathological examination. We report an unusual case of 22 years old Bangladeshi woman presented with a 6-month history of a lump on left breast. Although the lump was initially small, it began a rapid growth after 4 months. The swelling was localized and did not show any skin involvement or discharge and as she didn’t have any positive familial history of breast carcinoma her primary attending physician diagnosed it as a case of breast abscess. When local incision and drainage proved ineffective, she was referred to us. After doing an immunohistochemistry from incisional biopsy the diagnosis was confirmed as Diffuse Large B-cell Lymphoma. The patient was treated initially by chemotherapy with CHOP therapy followed by wide local excision. Early and accurate diagnosis of PBL is crucial for selecting the appropriate MDT treatment strategies to avert potentially harmful surgical interventions.

Download Full-text

Primary diffuse large B-cell lymphoma of the breast

Archive of oncology ◽

10.2298/aoo0904080p ◽

2009 ◽

Vol 17 (3-4) ◽

pp. 80-82

Author(s):

Lazar Popovic ◽

Darjana Jovanovic ◽

Gorana Matovina-Brko ◽

Dragana Petrovic ◽

Zoran Nikin ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Histological Subtype ◽

Primary Breast Lymphoma ◽

Large B Cell Lymphoma ◽

Breast Lymphoma ◽

Rare Location ◽

Large B Cell

Primary breast lymphoma is rare location of this disease. Diffuse large B-cell lymphoma is the most common histological subtype. We presented two cases of primary diffuse large B-cell lymphoma of the breast and reviewed a literature about this topic.

Download Full-text

EBV positive diffuse large B cell lymphoma: Evaluation of 29 cases with morphologic and immunohistochemical features of a rare entity

10.26226/morressier.596dfd58d462b80292387b3c ◽

2017 ◽

Author(s):

Hafize Ozdemir

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Rare Entity ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Intravascular Large B Cell Lymphoma of the Breast: A Rare Entity

Breast Cancer Basic and Clinical Research ◽

10.1177/11782234211050728 ◽

2021 ◽

Vol 15 ◽

pp. 117822342110507

Author(s):

Nitya Prabhakaran ◽

Hassan Sheikh ◽

Xinmin Zhang ◽

Silvat Sheikh-Fayyaz

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Review Literature ◽

Lymphoid Cells ◽

Prior History ◽

Rare Entity ◽

Treatment Protocols ◽

Large B Cell Lymphoma ◽

Large B Cell

Intravascular large B-cell lymphoma (IVLBCL) is a rare and high-grade disease of neoplastic lymphoid cells within the vascular lumina of small- to medium-sized vessels. The disease carries a grim prognosis despite robust treatment protocols. We discuss the case of a 58-year-old female who presented with mammographic screening abnormality which led to more investigations and ultimately to this diagnosis. The patient had no prior history of a lymphoma or in situ and invasive carcinoma of the breast. To our knowledge, IVLBCL of the breast is a very rare and an unusual location for this type of a lymphoma and so far, only five reported cases. Through our case report, we not only discuss the case but also review literature on this rare entity.

Download Full-text

Primary breast lymphoma of childhood: a case report and review of literature

BMC Pediatrics ◽

10.1186/s12887-021-03002-6 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Giulia A. Restivo ◽

Marta Pillon ◽

Lara Mussolin ◽

Clara Mosa ◽

Angela Guarina ◽

...

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

Local Treatment ◽

B Cell Lymphoma ◽

Left Breast ◽

Primary Breast Lymphoma ◽

Therapeutic Approaches ◽

Case Presentation ◽

Breast Lymphoma ◽

The Right

Abstract Background Primary breast lymphoma (PBL) is an extremely rare neoplasm in children; by definition, it manifests in the breast without evidence of lymphoma elsewhere, except ipsilateral axillary nodes. Case presentation We report a case of a 15-year-old girl diagnosed with diffuse large B-cell lymphoma (DLBCL) of the right breast: the patient received chemotherapy and rituximab, achieving complete remission. A literature review revealed other 11 cases of pediatric PBL; it mainly affects female adolescents and can involve right and left breast equally. Different histologic subtypes have been described, arising from both B-cell and T-cell. Therapeutic approaches were very different, from chemotherapy to local treatment with surgery and/or radiotherapy. Conclusions Our case is the first in which rituximab was administered, suggesting to be a promising therapy in B-cell PBL, as already demonstrated in pediatric B-cell lymphoma from other sites. Further investigations are needed to identify prognostic factors and establish the most effective treatment.

Download Full-text

Central nervous system involvement in patients with diffuse large B cell lymphoma: analysis of the risk factors and prognostic from a single-center retrospective cohort study

10.21203/rs.2.13767/v1 ◽

2019 ◽

Author(s):

Jingjing Ma ◽

Qing Li ◽

Jie Shao ◽

Yan Ma ◽

Zhiguang Lin ◽

...

Keyword(s):

Cell Lymphoma ◽

Elevated Serum ◽

B Cell Lymphoma ◽

Cns Lymphoma ◽

Absolute Count ◽

Cns Involvement ◽

Systemic Involvement ◽

Large B Cell Lymphoma ◽

Significant Difference ◽

Deep Lesion

Abstract Purpose The aim of this study was to identify the risk factors for central nervous system (CNS) involvement in systemic diffuse large B-cell lymphoma (DLBCL) patients and to explore prognostic for DLBCL patients with CNS involvement (relapse or progression). Method This was a retrospective cohort study in our hospital. Data were collected from all DLBCL patients diagnosed in our institutes from January, 2013 to June, 2018. Clinical information was collected from medical records. Result The participants included 138 patients with DLBCL. Among them, 38 patients were diagnosed as CNS lymphoma, including 15 patients exhibited CNS involvement while DLBCL were pathologically confirmed, and 23 patients developed CNS lymphoma during or after initial chemotherapy. The median disease-free interval to CNS involvement was 13 months. Multivariate analysis identified elevated serum lactate dehydrogenase(LDH) level [hazard ratio(HR)=4.035; 95% confidence interval(95%CI):1.147~14.195] was independent predictor of CNS involvement. The median progression-free survival (PFS) and overall survival (OS) time of DLBCL patients with CNS involved were 12.5 months and 22 months, respectively. Multivariate prognostic analysis showed that eastern cooperative oncology group (ECOG) score>2(P=0.018; HR=7.333; 95%CI:1.424~42.002), elevated serum LDH level (P=0.046; HR=6.510; 95%CI:1.035~40.949), deep lesion (P=0.005; HR=10.957; 95%CI:2.050~58.569), and CNS with systemic involvement (P=0.023; HR=2.730; 95%CI:1.151~6.479) were independent poor prognostic factors for the patients. The cases with lymphocyte absolute count >0.75×109/L (HR=0.047; 95%CI:0.003~0.732) had better prognosis. The OS of DLBCL patients with secondary CNS lymphoma was inferior to DLBCL patients without CNS involvement. There was no significant difference between the patients with CNS and extra-CNS involvement. There was no significant difference between the patients with CNS involvement and stage III-IV DLBCL cases without CNS lymphoma. Conclusion In conclusion, elevated serum LDH was independent high-risk factor for secondary CNS lymphoma. For patients DLBCL with CNS involvement, ECOG score>2, elevated serum LDH level, deep lesion, lymphocyte absolute count ≤0.75×109/L and CNS with systemic involvement retained a significant association with outcome.

Download Full-text